Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8513 | 1.00 | MAOB (0.71) | MAOBMAOA | |
| SCHEMBL11070224 | 0.99 | MAOB (0.72) | MAOBMAOA | |
| SCHEMBL30546591 | 0.96 | MAOB (0.70) | MAOBMAOA | |
| SCHEMBL252282 | 0.96 | MAOB (0.70) | MAOBMAOA | |
| SCHEMBL2842062 | 0.93 | MAOB (0.80) | MAOBMAOA | |
| SCHEMBL17848639 | 0.92 | MAOB (0.68) | MAOBMAOA | |
| SCHEMBL29923843 | 0.92 | MAOB (0.68) | MAOBMAOA | |
| SCHEMBL1036438 | 0.89 | MAOB (0.67) | MAOBMAOA | |
| SCHEMBL14188953 | 0.88 | MAOB (0.57) | MAOBMAOA | |
| SCHEMBL11276922 | 0.88 | MAOB (0.65) | MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117288847-A | Method for measuring content of related substances and preservative of aripiprazole oral solution | 万特制药(海南)有限公司 | 2023-12-26 | — | — | CN | claimed |
| CN-115340494-A | Synthesis method of high-purity aripiprazole | 安徽修一制药有限公司 | 2022-11-15 | — | — | CN | claimed |
| CN-121800721-A | Aripiprazole Process for preparing azoles | 浙江工业大学 | 2026-04-07 | — | — | CN | disclosed |
| US-20260076975-A1 | TPK AGONIST AND METHOD FOR USING SAME TO TREAT NEURODEGENERATIVE DISEASES | SHANGHAI RAISING PHARMACEUTICAL CO LTD (CN) | 2026-03-19 | — | — | US | disclosed |
| EP-4628098-A1 | TPK AGONIST AND METHOD FOR USING SAME TO TREAT NEURODEGENERATIVE DISEASES | Shanghai Raising Pharmaceutical Co., Ltd. (CN) | 2025-10-08 | — | — | EP | disclosed |
| CN-114008058-B | Prodrugs of CDK inhibitors for the treatment of cancer | 润佳（苏州）医药科技有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-116730981-B | 5-HT2AReceptor inhibitor or inverse agonist, preparation method and application thereof | 山东绿叶制药有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118121699-A | TPK agonists and methods of using the same for treating neurodegenerative diseases | 上海日馨医药科技股份有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-116178307-B | Synthesis method of 1- (2, 3-dichlorophenyl) piperazine hydrochloride | 浙江大洋生物科技集团股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-117924169-A | Dihydroquinoline derivative and pharmaceutical application thereof in resisting influenza | 山东大学齐鲁医院 | 2024-04-26 | — | — | CN | disclosed |
| CN-110054694-B | Antibodies to aripiprazole hapten and uses thereof | 詹森药业有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-115340494-A | Synthesis method of high-purity aripiprazole | 安徽修一制药有限公司 | 2022-11-15 | — | — | CN | disclosed |
| CN-115340494-A | Synthesis method of high-purity aripiprazole | 安徽修一制药有限公司 | 2022-11-15 | — | — | CN | disclosed |
| CN-108069900-B | Preparation method and application of aripiprazole hydrochloride | 齐鲁制药有限公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-114728933-A | 5-HT2AReceptor inhibitor or inverse agonist, preparation method and application thereof | 山东绿叶制药有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-109970637-B | Aripiprazole hapten and application thereof in immunoassay | 詹森药业有限公司 | 2022-04-19 | — | — | CN | disclosed |
| CN-108484496-B | Aripiprazole hapten and application thereof in immunoassay | 詹森药业有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-114177868-A | Preparation method and device of aripiprazole | 辰欣药业股份有限公司 | 2022-03-15 | — | — | CN | disclosed |
| EP-3953350-A1 | D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF | The United States of America, as Represented by The Department of Health and Human Services (US) | 2022-02-16 | — | — | EP | disclosed |
| CN-114044772-A | Epipiprazole synthesis method and intermediate thereof | 浙江国邦药业有限公司 | 2022-02-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076975-A1 | TPK AGONIST AND METHOD FOR USING SAME TO TREAT NEURODEGENERATIVE DISEASES | PDXK, NADK, HYPK | MAOB 144/4885MAOA 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.